Mystic Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Mystic Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18M	Sell	25,400 -300	-1%	-$14.4K	0.25%	88
2026 Q1	$1.33M	Hold	25,700	–	–	0.31%	81
2025 Q4	$1.28M	Hold	25,700	–	–	0.29%	84
2025 Q3	$1.23M	Hold	25,700	–	–	0.28%	85
2025 Q2	$810K	Sell	25,700 -2,300	-8%	-$73.7K	0.2%	105
2025 Q1	$917K	Sell	28,000 -200	-0.7%	-$7.09K	0.24%	95
2024 Q4	$1.02M	Sell	28,200 -40	-0.1%	-$1.41K	0.27%	87
2024 Q3	$881K	Buy	28,240 +300	+1%	+$9.36K	0.33%	80
2024 Q2	$747K	Sell	27,940 -1,300	-4%	-$37.7K	0.3%	83
2024 Q1	$997K	Sell	29,240 -100	-0.3%	-$2.98K	0.41%	73
2023 Q4	$849K	Sell	29,340 -500	-2%	-$13.3K	0.41%	75
2023 Q3	$823K	Buy	29,840 +500	+2%	+$15.2K	0.46%	72
2023 Q2	$882K	Sell	29,340 -1,400	-5%	-$49K	0.47%	72
2023 Q1	$1.11M	Hold	30,740	–	–	0.61%	59
2022 Q4	$1.1M	Sell	30,740 -100	-0.3%	-$3.48K	0.62%	59
2022 Q3	$1.04M	Sell	30,840 -1,750	-5%	-$56.9K	0.67%	54
2022 Q2	$942K	Sell	32,590 -500	-2%	-$14.3K	0.57%	62
2022 Q1	$1.07M	Buy	33,090 +1,000	+3%	+$30.7K	0.57%	62
2021 Q4	$935K	Buy	+32,090	New	+$974K	0.44%	71

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Mystic Asset Management's SUPN Position: Q2 2026 in Review

Mystic Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 1.2% in Q2 2026, selling an estimated $14.4K and leaving 25,400 shares worth $1.18M. The position accounts for 0.25% of the portfolio, ranked #88.

Mystic Asset Management first reported a position in SUPN in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.33M in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Mystic Asset Management held 25,400 shares of Supernus Pharmaceuticals worth $1.18M as of Q2 2026.
Mystic Asset Management sold 300 Supernus Pharmaceuticals shares in Q2 2026, an estimated $14.4K.
Supernus Pharmaceuticals made up 0.25% of Mystic Asset Management's portfolio in Q2 2026, its #88 holding.
Mystic Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Mystic Asset Management's Supernus Pharmaceuticals position peaked at $1.33M in Q1 2026.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Mystic Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.